Drug profile

The FDA adverse-event record for Afoxalaner

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Afoxalaner. See the species affected, top reactions, and outcomes below.

10
adverse-event reports
10.0%
death-coded share
Dog
most-reported species
4
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
1
Deaths Reported
10.0%
Death Rate

Active Ingredients

Afoxalaner

Administration Routes

OralUnknown

Species Affected

Dog 10

Most Affected Breeds

Retriever - Golden 2
Retriever - Labrador 2
Catahoula Leopard Dog 2
Doberman Pinscher 1
Saint Bernard Dog 1
Bulldog - English 1
Shepherd Dog - Australian 1

Most Reported Reactions

Vomiting 4
Lethargy (see also Central nervous system depression in 'Neurological') 2
Other abnormal test result NOS 2
Eosinophilia 2
Urinary tract infection 2
Lack of efficacy (endoparasite) - heartworm 2
Elevated symmetrical dimethylarginine (SDMA) 2
Hypocortisolaemia 2
Lack of efficacy (ectoparasite) - tick NOS 2
Facial swelling (see also 'Skin') 2
Local swelling (not application site) 2
Product label issues 2

Outcome Breakdown

Outcome Unknown
6 (60.0%)
Recovered/Normal
3 (30.0%)
Died
1 (10.0%)

Afoxalaner Adverse Event Insights

10 reports name Afoxalaner; 1 recorded a death outcome (10.0% of reported events, not a population-level mortality rate). Active ingredient: Afoxalaner. Administration routes: Oral, Unknown.

By species: Dog (10 reports). By breed: Retriever - Golden (2), Retriever - Labrador (2), Catahoula Leopard Dog (2).

Leading clinical signs: Vomiting (4), Lethargy (see also Central nervous system depression in 'Neurological') (2), Other abnormal test result NOS (2), Eosinophilia (2). Outcome, 10 coded reports: Outcome Unknown leads at 60.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.